Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin
versus their isolated components in treatment of hypertension and dyslipidemia.